Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
2008 1
2013 1
2017 1
2018 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Quinaya
Page 1
Treatment with COLchicine in hospitalized patients affected by COVID-19: The COLVID-19 trial.
Perricone C, Scarsi M, Brucato A, Pisano P, Pigatto E, Becattini C, Cingolani A, Tiso F, Prota R, Tomasoni LR, Cutolo M, Tardella M, Rozza D, Zerbino C, Andreoni M, Poletti V, Bartoloni E, Gerli R; COLVID-19 study group, under the auspices of the Italian Society of Rheumatology (SIR), the Italian Society of Infectious and Tropical Diseases (SIMIT) and the Italian Thoracic Society (ITS-AIPO). Perricone C, et al. Eur J Intern Med. 2023 Jan;107:30-36. doi: 10.1016/j.ejim.2022.10.016. Epub 2022 Oct 31. Eur J Intern Med. 2023. PMID: 36396522 Free PMC article. Clinical Trial.
Older age (>60 years, P=0.025), P/F<275 mmHg (P=0.005), AST>40 U/L (P<0.001), pre-existent heart (P=0.02), lung (P=0.003), upper-gastrointestinal (P=0.014), lower-gastrointestinal diseases (P=0.009) and cancer ( …
Older age (>60 years, P=0.025), P/F<275 mmHg (P=0.005), AST>40 U/L (P<0.001), pre-existent heart ( …
Does platelet-rich fibrin have a role in osseointegration of immediate implants? A randomized, single-blind, controlled clinical trial.
Diana C, Mohanty S, Chaudhary Z, Kumari S, Dabas J, Bodh R. Diana C, et al. Int J Oral Maxillofac Surg. 2018 Sep;47(9):1178-1188. doi: 10.1016/j.ijom.2018.01.001. Epub 2018 May 7. Int J Oral Maxillofac Surg. 2018. PMID: 29402513 Clinical Trial.
A significant increase in implant stability was noted in both groups over the 3-month period (implant stability quotient: study group 56.5818.81 to 71.327.82; control group 60.6111.49 to 70.068.96; P=0.01). No significant difference was observed between the groups in terms …
A significant increase in implant stability was noted in both groups over the 3-month period (implant stability quotient: study group 56.581 …
Is the routine practice of antibiotic prescription and microbial culture and antibiotic sensitivity testing justified in primary maxillofacial space infection patients? A prospective, randomized clinical study.
Kumari S, Mohanty S, Sharma P, Dabas J, Kohli S, Diana C. Kumari S, et al. Among authors: diana c. J Craniomaxillofac Surg. 2018 Mar;46(3):446-452. doi: 10.1016/j.jcms.2017.11.026. Epub 2017 Dec 20. J Craniomaxillofac Surg. 2018. PMID: 29311020 Clinical Trial.
There was no statistically significant difference between the two groups for the five study parameters (p < 0.05). Of the total pus specimens, 75% had no significant bacterial growth, or grew 'oral flora'/contaminants, while only 25% grew specific bacteria. ...

There was no statistically significant difference between the two groups for the five study parameters (p < 0.05). Of the total pu

…
Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement.
Racadot S, Mercier M, Dussart S, Dessard-Diana B, Bensadoun RJ, Martin M, Malaurie E, Favrel V, Housset M, Durdux C, Journel C, Calais G, Huet J, Pillet G, Hennequin C, Haddad E, Diana C, Blaska-Jaulerry B, Henry-Amar M, Géhanno P, Baillet F, Mazeron JJ. Racadot S, et al. Among authors: diana c. Radiother Oncol. 2008 May;87(2):164-72. doi: 10.1016/j.radonc.2007.12.021. Epub 2008 Jan 25. Radiother Oncol. 2008. PMID: 18222010 Clinical Trial.
With a median follow-up of 106 months (95% confidence interval (CI) [92-119]), the 2-year rate of loco-regional control was 73% (95% CI: 0.61-0.84) in the combined treatment group and 68% (95% CI: 0.57-0.80) in the radiotherapy group (p=0.26). Overall survival did not diff …
With a median follow-up of 106 months (95% confidence interval (CI) [92-119]), the 2-year rate of loco-regional control was 73% (95% CI: 0.6 …
The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma. A prospective, multicentre study (RTEP3).
Palie O, Michel P, Ménard JF, Rousseau C, Rio E, Bridji B, Benyoucef A, Meyer ME, Jalali K, Bardet S, M'vondo CM, Olivier P, Faure G, Itti E, Diana C, Houzard C, Mornex F, Di Fiore F, Vera P. Palie O, et al. Among authors: diana c. Eur J Nucl Med Mol Imaging. 2013 Sep;40(9):1345-55. doi: 10.1007/s00259-013-2450-7. Epub 2013 May 29. Eur J Nucl Med Mol Imaging. 2013. PMID: 23715903 Clinical Trial.
RESULTS: SUVmax, SUVmean and TLG decreased significantly between PET1 (t0) and PET2 (d21; p < 0.0001). The TV significantly decreased only when assessed as TVp (p = 0.02); TV40 did not decrease significantly. ...

RESULTS: SUVmax, SUVmean and TLG decreased significantly between PET1 (t0) and PET2 (d21; p < 0.0001). The TV significantly decrea

…